Project Grant R01CA315098
Award Date 7/1/26
Completion Date 6/30/31
Dollars Obligated $587K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
New York, NY 10032, USA
Similar Awards
- Federal Project Grant Award Summary The National Cancer Institute (NCI) awarded The Trustees of Columbia University in the City of New York $501,422 under the Cancer Biology Research program (CFDA 93.396) on May 1, 2026, for a project titled "Advancing a Novel Synthetic Lethal Target by Exploiting Ribosomal Stress in CH9P21.3-Deleted or MSI-H Cancers." The project will run through April 30, 2031, and focuses on developing precision oncology therapies targeting the PELO-HBS1L...
- Federal Project Grant Award Summary The National Cancer Institute (NCI) awarded The Trustees of Columbia University in the City of New York a $630,089 Project Grant under the Cancer Cause and Prevention Research program (CFDA 93.393) effective May 1, 2026, with an anticipated completion date of April 30, 2031. This research initiative focuses on characterizing the molecular functions of SMARCAL1, a DNA translocase protein implicated in suppressing anti-tumor immune responses. The grant...
- Federal Project Grant Award Summary Dana-Farber Cancer Institute, Inc. received a $683,075 Project Grant award from the National Cancer Institute under the Cancer Cause and Prevention Research program (CFDA 93.393), effective March 24, 2026 through February 28, 2031. The award supports basic research investigating the mitotic function of the protein 53BP1 and its negative regulator TIRR in maintaining genome stability and preventing cancer-related chromosomal abnormalities. The research project,...
- Federal Grant Award Summary The National Cancer Institute awarded $125,619 to the Stowers Institute for Medical Research under the Cancer Cause and Prevention Research program (CFDA 93.393) effective August 1, 2025, through July 31, 2030. This Project Grant supports research into centromere biology and chromosome segregation mechanisms that contribute to genomic instability—a hallmark of cancer development. The primary deliverables include experimental research characterizing how natural...
- Federal Project Grant Award Summary The National Cancer Institute (NCI) awarded $182,755.00 to Cold Spring Harbor Laboratory through the Cancer Biology Research program (CFDA 93.396) to support research on genetic technology development for elucidating lineage plasticity mechanisms in cancer. The project, which commenced on August 21, 2025, and is scheduled for completion on July 31, 2030, will deliver advanced genetic screening technologies and methodologies designed to probe lineage identity...
- Federal Project Grant Award Summary The National Cancer Institute (NCI) awarded Sloan-Kettering Institute for Cancer Research a $3.2 million Project Grant under the Cancer Cause and Prevention Research program (CFDA 93.393) beginning August 1, 2025, and concluding July 31, 2029. This research initiative investigates the mechanisms of extrachromosomal DNA (ecDNA) segregation and repair in cancer cells, with emphasis on understanding how ecDNA's circular topology contributes to tumor progression...
- Federal Grant Award Summary The National Cancer Institute (NCI) awarded $270,683 to the New York Genome Center, Inc. (NYGC) under the Cancer Biology Research program (CFDA 93.396) on May 5, 2026, with an ultimate completion date of April 30, 2029. This Project Grant funds the development and validation of Paired-Break-Seq, a novel high-throughput single-cell multiomics sequencing technique designed to simultaneously analyze DNA double-strand breaks (DSBs), single-strand breaks (SSBs), and...
- Federal Project Grant Award Summary The National Cancer Institute awarded a Project Grant of $495,715 to the Sloan-Kettering Institute for Cancer Research under the Cancer Biology Research program (CFDA 93.396) on August 5, 2025, with a completion date of July 31, 2030. This award funds fundamental research to decipher the pathogenesis and therapeutic vulnerabilities in germline RUNX1-mutated acute myeloid leukemia (AML). The research focuses on understanding how germline RUNX1 mutations...
- Federal Project Grant Award Summary The National Cancer Institute (NCI) awarded Columbia University's Health Sciences Division a Project Grant totaling $257,472 under the Cancer Research Manpower program (CFDA 93.398) on September 6, 2025, with completion targeted for March 6, 2029. This award supports research investigating the impact of genomic variants on T cell anti-tumor activity, with the ultimate goal of enhancing cellular immunotherapy efficacy for patients with melanomas and leukemias...
- Federal Project Grant Award Summary The National Cancer Institute (NCI) awarded Sloan-Kettering Institute for Cancer Research $323,860 through the Cancer Research Manpower program (CFDA 93.398) to support research investigating the role of mutagenic DNA repair mechanisms in cancer cell persistence and acquired drug resistance. The award, effective August 18, 2025, with a completion date of April 30, 2028, funds a research project examining how cellular stress from anti-cancer drugs rewires DNA...